Combined with our previous research, we came to this conclusion that it would be reasonable to hypothesize that Notch1 signaling inhibition may favor anti-tumor and it might provide a new target for EOC, our study provides laboratory evidence for the future use of Notch1 inhibitors in ovarian cancer. This evidence concerns the gene NOTCH1 and ovarian cancer.